Supplementary Information for:

Synthesis and biological evaluation of RGD peptides with the ^{99m}Tc/¹⁸⁸Re chelated iminodiacetate core: Highly enhanced uptake and excretion kinetics of theranostics against tumor angiogenesis

Byung Chul Lee,[†] Byung Seok Moon,[†] Ji Sun Kim,[†] Jae Ho Jung,[†] Hyun Soo Park,[†] John A. Katzenellenbogen,[‡] Sang Eun Kim^{†,§,}*

^aDepartment of Nuclear Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul 110-799, Korea; ^bDepartment of Chemistry, University of Illinois, Urbana, Illinois 61801, USA; ^cDepartment of Nano Science and Technology, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 151-742, Korea

Synthesis of ^{99m}Tc-IDA-D-[c(RADfK)]₂ and ^{185/187}Re-IDA-D-[c(RADfK)]₂

The cyclic pentapeptides, i.e., cyclic-Arg(Pbf)-Gly-Asp(O'Bu)-D-Phe-Lys-NH₂ and cyclic-Arg(Pbf)-Ala-Asp(O'Bu)-D-Phe-Lys-NH₂ (for ^{99m}Tc-IDA-D-[c(RADfK)]₂) were prepared using solid support coupling protocol according to previously described methods. ^{21,27} The ^{99m}Tc-IDA-D-[c(RADfK)]₂ (t_R = 18.6 min by HPLC conditon A), ^{185/187}Re-IDA-D-[c(RADfK)]₂ [t_R = 19.2 min by HPLC conditon A, MS (ESI) m/z 1448.7 (M+H)⁺] and IDA-D-[c(RADfK)]₂ [MS (ESI) m/z 1448.7 (M+H)⁺] were prepared by according to same procedure of ^{99m}Tc-IDA-D-[c(RGDfK)]₂, ^{185/187}Re-IDA-D-[c(RGDfK)]₂ and IDA-D-[c(RGDfK)]₂, respectively.

Table 1. HPLC data of ^{185/187}Re or ^{99m}Tc-IDA-RGD Analogs (1-6)

^aHPLC condition A

- semi-Preparative column (Agilent, Eclipse XDB-C18 column, 5 μ , 9.4 \times 250 mm)
- UV detector (Thermo, SectraSystem UV3000 set at 214 nm) with a gamma-ray detector (Bioscan, Flow-Count fitted with a NaI(Tl) detector)
- Eluant: 0 min (20% CH₃CN/H₂O/0.1% TFA); 5 min (20% CH₃CN/H₂O/0.1% TFA); 40 min (60% CH₃CN/H₂O/0.1% TFA)
- Flow rate: 2 mL/min

^bHPLC condition B

- Analytical column (YMC, YMC-triart-C18 column, 5 μ , 4.6 \times 250 mm)
- UV detector (Thermo, SectraSystem UV2000 set at 214 nm)
- Eluant: 0 min (20% CH₃CN/H₂O/0.1% TFA); 5 min (20% CH₃CN/H₂O/0.1% TFA); 20 min (80% CH₃CN/H₂O/0.1% TFA)
- Flow rate: 0.7 mL/min

Compound	$t_R \left(\min \right)^a$	$t_R \left(\min \right)^b$	<i>k'</i>
1	21.8	15.1	1.90
2	22.1	15.5	1.98
3	19.2	14.8	1.85
4	20.6	15.1	1.90
5	21.4	15.4	1.96
6	18.4	14.7	1.83

Table 2. Extraction efficiency of the organ homogenates and the blood samples 30 min and 120 min postinjection.

	Extraction Efficiency [%] ^a	
	30 min	120 min
blood	47.8	55.9
urine	97.1	93.2
tumor	93.2	87.3
liver	86.5	62.3
kidney	95.5	88.6

^aAmount of activity of soluble fractions, which was eluted form the C-18 Sep-Pak cartridge using acetonitrile.